Bristol Myers drops another CytomX program

Bris­tol My­ers Squibb dropped an­oth­er CT­LA-4 pro­gram from its decade-long re­search col­lab­o­ra­tion with Cy­tomX af­ter the big phar­ma re­viewed its port­fo­lio.

Cy­tomX an­nounced the change in its 2023 fi­nan­cial re­sults on Mon­day, not­ing that the com­pa­nies are still col­lab­o­rat­ing on mul­ti­ple pre­clin­i­cal pro­grams, in­clud­ing T cell en­gagers. It was no­ti­fied by BMS on March 6 that the an­ti-CT­LA-4, BMS-986288, won’t ad­vance be­yond its cur­rent tri­al. That Phase II study is in­ves­ti­gat­ing the drug as a monother­a­py and in com­bi­na­tion with nivolum­ab for pa­tients with ad­vanced sol­id tu­mors and is set to wrap up in April, ac­cord­ing to clin­i­cal­tri­als.gov.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.